Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007

Vaccine

Volumn 27, Issue 2, 2009, Pages 290-297

  Niu, Manette T ^a   Ball, Robert ^a   Woo, Emily Jane ^a   Burwen, Dale R ^a   Knippen, Maureen ^b   Braun, M Miles ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b Office of Compliance and Biologic Quality   (United States)

Author keywords

Anthrax vaccine; Post marketing surveillance; VAERS

Indexed keywords

ANTHRAX VACCINE; HEPATITIS VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; SMALLPOX VACCINE; TYPHOID VACCINE;

ADULT; ALOPECIA; AMYOTROPHIC LATERAL SCLEROSIS; ANKYLOSING SPONDYLITIS; ANXIETY; APLASTIC ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; ATTENTION DISTURBANCE; CHOLESTEROL BLOOD LEVEL; CYST; DEEP VEIN THROMBOSIS; DEPRESSION; DIZZINESS; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; DRY SKIN; EDEMA; FATIGUE; FEMALE; FOCAL GLOMERULOSCLEROSIS; GASTRITIS; GASTROESOPHAGEAL REFLUX; HEADACHE; HEART INFARCTION; HUMAN; HYPOTHYROIDISM; INCIDENCE; INJECTION SITE REACTION; INSOMNIA; IRRITABLE COLON; KIDNEY DISEASE; LUNG EMBOLISM; LYMPHOMA; MALE; MEMORY DISORDER; MIGRAINE; MORTALITY; MULTIPLE ORGAN FAILURE; MULTIPLE SCLEROSIS; MUSCLE TWITCH; MYALGIA; MYELITIS; MYOCARDITIS; PAIN; PNEUMONIA; POLYARTERITIS NODOSA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; RASH; RHEUMATOID ARTHRITIS; SIDE EFFECT; SLEEP DISORDER; SYSTEMIC LUPUS ERYTHEMATOSUS; UNPLANNED PREGNANCY; VACCINATION; VAGINA BLEEDING;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTHRAX; ANTHRAX VACCINES; BAYES THEOREM; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; VACCINATION; VACCINES; YOUNG ADULT;

EID: 57249088997     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.10.044     Document Type: Article

References (69)

1. In: Joellenbeck L.M., Zwanziger L.L., Durch J.S., and Strom B.L. (Eds). The anthrax vaccine: is it safe? Does it work? (2002), Institute of Medicine, National Academy Press, Washington D.C.
2. Sever J.L., Brenner A.I., Gale A.D., Lyle J.M., Moulton L.H., and West D.J. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol Drug Saf 11 (2002) 189-202
3. Sever J.L., Brenner A.I., Gale A.D., Lyle J.M., Moulton L.H., Ward B.J., et al. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol Drug Saf 13 (2004) 825-840
4. Review of VAERS Anthrax vaccine reports received through 8/15/05, and adverse event reports submitted to Docket No. 1980N-0208, December 13, 2005, FDA Weblink: http://www.fda.gov/ohrms/dockets/dockets/80n0208/80n-0208-bkg0006-19-Ref -17-VAERS-Vol225.pdf (Reference 17).
5. Centers for Disease Control and Prevention. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. Morb Mort Wkly Rep 2002;51(45):1024-6.
6. Advisory Committee on Immunization Practices. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices. Clin Toxicol 2001;39(1):85-100.
7. Blanchard J.C., Haywood Y., Stein B.D., Tanielian T.L., Stoto M., and Lurie N. In their own words: lessons learned from those exposed to Anthrax. Am J Public Health 95 3 (2005) 489-495
8. Murphy D., Dandeker C., Horn O., Hotopf M., Hull L., Jones M., et al. UK armed forces responses to an informed consent policy for anthrax vaccination: a paradoxical effect?. Vaccine 24 16 (2006) 3109-3114
9. Ackermann D., Chapman S., and Leask J. Media coverage of anthrax vaccination refusal by Australian Defense Force Personnel. Vaccine 23 3 (2004) 411-417
10. Fowler G.L., Baggs J.M., Weintraub E.S., Martin S.W., McNeil M.M., and Gust D.A. Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program. Pharmacoepidemiol Drug Saf 15 (2006) 880-888
11. Gillis J. No Hope for stockpile of new Anthrax vaccine by November. The Washington Post; March 17, 2006. p. A01.
12. Bioport Corporation. Anthrax Vaccine Adsorbed (Biothrax TM), Package Insert; 2002.
13. Brachman P.S., Gold H., Plotkin S.A., Fekety F.R., Werrin M., and Ingraham N.R. Field evaluation of a human anthrax vaccine. Am J Public Health 56 (1962) 632-645
14. Wright G.G., Green T.W., and Kanode R.G. Studies on immunity in anthrax: V. Immunizing activity of alum-precipitated protective antigen. J Immunol 73 6 (1954) 387-391
15. Pittman P.R., Gibbs P.H., Cannon T.L., and Friedlander A.M. Anthrax vaccine: short-term safety experience in humans. Vaccine 20 (2002) 972-978
16. Payne D.C., Franzke L.H., Stehr-Green P.A., Schwartz B., and McNeil M.M. Development of the Vaccine Analytic Unit's research agenda for investigating potential adverse events associated with anthrax vaccine adsorbed. Pharmacoepidemiol Drug Saf 16 (2007) 46-54
17. DuMouchel W. Bayesian data mining in large frequency tables with an application to the FDA Spontaneous Reporting System. Am Stat 53 3 (1999) 177-190
18. Banks D., Woo E.J., Burwen D.R., Perucci P., Braun M.M., and Ball R. Comparing data mining methods on the VAERS database. Pharmacoepidemiol Drug Saf 14 (2005) 601-609
19. Woo E.J., Ball R., Burwen D.R., and Braun M.M. Effects of stratification on data mining in the Vaccine Adverse Event Reporting System (VAERS). Drug Saf 31 8 (2008) 677-774
20. Niu M.T., Erwin D.E., and Braun M.M. Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. Vaccine 19 (2001) 4627-4634
21. Woo E.J., et al. Adverse events after hepatitis AB combination vaccine. Vaccine 24 14 (2006) 2685-2691 [Epub 2005 Nov 9]
22. Niu MT, Salive ME, Ellenberg SS. Post-marketing surveillance for adverse events after vaccination: the national Vaccine Adverse Event Reporting System (VAERS). A MEDWATCH Continuing Education Article; 1998.
23. 21CFR600.80 (Code of Federal Regulations, Title 21, Part 600, Sec. 600.80) Postmarketing reporting of adverse experiences.
24. Fukuda K., Nisenbaum R., Stewart G., Thompson W.W., Robin L., Washko R.M., et al. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. J Am Med Assoc 280 11 (1998) 981-988
25. Muellenhoff M., Cukrowski T., Morgan M., and Dorton D. Oral pemphigus vulgaris after anthrax vaccine administration: association or coincidence?. J Am Acad Dermatol 50 1 (2004) 136-139
26. Vasudev M., and Zacharisen M.C. New-onset rheumatoid arthritis after anthrax vaccination. Ann Allergy Asthma Immunol 97 (2006) 110-112
27. Muniz A.E. Lymphocytic vasculitis associated with the anthrax vaccine: case report and review of anthrax vaccination. J Emerg Med 25 3 (2003) 271-276
28. Kerrison J.B., Lounsbury D., Thirkill C.E., Lane R.G., Schatz M.P., and Engler R.M. Optic neuritis after anthrax vaccination. Ophthalmology 109 1 (2002) 99-104
29. Payne D.C., Rose C.E., Kerrison J., Aranas A., Duderstadt S., and McNeil M.M. Anthrax vaccination and risk of Optic Neuritis in the United States military, 1998-2003. Arch Neurol 63 (2006) 871-875
30. Begier E.M., Langford C.A., Sneller M.C., Wise R.P., and Ball R. Polyarteritis nodosa reports to the Vaccine Adverse Event Reporting System (VAERS): implications for assessment of suspected vaccine-provoked vasculitis. J Rheumatol 31 11 (2004) 2181-2188
31. Holmstedt-Mark B.J., Smolinsky F., and Bradshaw D. The Psychosocial aspect of the anthrax vaccine: "The Dover Experience". Mil Med 166 12 Suppl. (2001) 36-40
32. Pittman P.R., Kim-Ahn G., Pifat D.Y., Coonan K., Gibbs P., Little S., et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20 (2002) 1412-1420
33. McNeil M.M., Chiang I.S., Wheeling J.T., and Zhang Y.J. Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967-1972 study and review of the 1955-2005 medical literature. Pharmacoepidemiol Drug Saf 16 (2007) 259-274
34. Pittman P.R. Aluminum-containing vaccine associated gender adverse events: role of route of administration and gender. Vaccine 20 (2002) S48-S50
35. Yoshida S., Mulder D.W., Kurland L.T., Chu C.P., and Okazaki H. Follow-up study on amyotrophic lateral sclerosis in Rochester, Minn., 1925 through 1984. Neuroepidemiology 5 (1986) 61-70
36. Juergens S.M., Kurland L.T., Okazaki H., and Mulder D.W. ALS in Rochester, Minnesota, 1925-1977. Neurology 30 (1980) 463-470
37. O'Toole O., Traynor B.J., Brennan P., Sheehan C., Frost E., Corr B., et al. Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004. J Neurol Neurosurg Psychiatry 79 (2008) 30-32
38. Kurtzke J.F. Epidemiology of amyotrophic lateral sclerosis. Adv Neurol 36 (1982) 281-302
39. Horner R.D., Kamins K.G., Feussner J.R., Grambow S.C., Hoff-Lindquist J., Harati Y., et al. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology 61 2 (2003) 742-749
40. Haley R.W. Excess incidence of ALS in young Gulf War veterans. Neurology 61 2 (2003) 750-756
41. Weisskopf M.G., O'Reilly E.J., McCullough M.L., Calle E.E., Thun M.J., et al. Prospective study of military service and mortality from ALS. Neurology 64 1 (2005) 32-37
42. Beghi E., and Morrison K.E. ALS and military service. Neurology 64 1 (2005) 6-7
43. Testa D., Lovati R., Ferrarini M., Salmoiraghi F., and Filippini G. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. ALS 5 (2004) 208-212
44. Wraith D.C., Goldman M., and Lambert P.H. Vaccination and autoimmune disease: what is the evidence?. Lancet 362 (2003) 1659-1666
45. Schonberger L.B., Bregman D.J., Sullivan-Bolyai J.Z., Keenlyside R.A., Ziegler D.W., Retailliau H.F., et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States 1976-1977. Am J Epidemiol 110 2 (1979) 105-123
46. Miron D., and Peter G. Recurrent thrombocytopenic purpura after repeated Measles-Mumps-Rubella vaccination. Pediatrics 97 5 (1996) 738-739
47. Beeler J., Varricchio F., and Wise R. Thrombocytopenia after immunization with measles vaccines: review of the Vaccine Adverse Events Reporting System (1990 to 1994). Pediatr Infect Dis J 15 1 (1996) 88-90
48. Rajantie J., et al. Vaccination associated thrombocytopenic purpura in children. Vaccine 25 10 (2007) 1838-1840
49. France E., Glanz J., Xu S., Hambidge S., Yamasaki K., Black S., et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 121 3 (2008) e687-e692
50. Black C., Kaye J.A., and Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol 55 (2003) 107-111
51. Jacobson D.L., Gange S.J., Rose N.R., and Graham N.M.H. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopath 84 3 (1997) 223-243 [Epub 2006 Nov 9]
52. Eaton W.W., Rose N.R., Kalaydjian A., Pedersen M.G., and Mortensen P.B. Epidemiology of autoimmune diseases in Denmark. J Autoimmunity 29 (2007) 1-9
53. Lawrence R.C., Hochberg M.C., Kelsey J.L., McDuffie F.C., Medsger T.A., Felts W.R., et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 16 4 (1989) 427-441
54. Linos A., Worthington J.W., O'Fallon W.M., and Kurland L.T. The Epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol 111 (1980) 87-98
55. Hochberg M.C., and Spector T.D. Epidemiology of rheumatoid arthritis: update. Epidemiologic Rev 12 (1990) 247-252
56. Alamanos Y., Voulgari P.V., and Drosos A.A. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Sem Arthritis Rheumatism 36 3 (2006) 182-188
57. Kurtzke J.F. The current neurologic burden of illness and injury in the United States. Neurology 32 (1982) 1207-1214
58. Berman M., Feldman S., Alter M., Zilber N., and Kahana E. Acute transverse myelitis: incidence and etiologic considerations. Neurology 31 (1981) 966-971
59. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002;59(2):499-505.
60. Shbeeb M., Uramtoto K.M., Gibson L.E., O'Fallon W.M., and Gabriel S.E. The Epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 27 5 (2000) 1247-1250
61. Gladman D.D., Antoni C., Mease P., Clegg D.O., and Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheumat Dis 64 Suppl. 2 (2005) ii14-ii17
62. Neimann A.L., Porter S.B., and Gelfand J.M. The epidemiology of psoriasis. Expert Rev Dermatol 1 1 (2006) 63-75
63. Zanardi L.R., Haber P., Mootrey G.T., Niu M.T., Wharton M., et al. Intussusception among recipients of rotavirus vaccine: reports to the Vaccine Adverse Event Reporting System. Pediatrics 107 6 (2001) e97
64. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. Morb Mort Wkly Rep 1999;48(27)577-81.
65. Centers for Disease Control and Prevention. Suspension of rotavirus vaccine after reports of intussusception-United States, 1999. Morb Mort Wkly Rep 2004;53(34):786-9.
66. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344 8 (2001) 564-572
67. Eaton K.M., Messer S.C., Garvey Wilson A.L., and Hoge C.W. Strengthening the validity of population-based suicide rate comparisons: an illustration using U.S. military and civilian data. Suicide Life Threat Behav 36 2 (2006) 182-191
68. McNeil M.M., Duderstadt S., Davila J.C., Sabatier J., Zhang Y.J., Ma G.H.W., et al. Update from the Vaccine Analytic Unit (VAC): a unique post marketing vaccine safety research infrastructure using the Defense Medical Surveillance System (DMSS). 42nd National Immunization Conference. CDC, Atlanta GA, poster presentation (169), March 18 (2008)
69. Davila J.C., Duderstadt S., Sabatier J., Ma G.H., Zhang Y.J., and McNeil M.M. Anthrax vaccine adsorbed and risk of idiopathic atrial fibrillation in the United States military, 1998-2005. 42nd National Immunization Conference. CDC, Atlanta GA, poster presentation (144), March 18 (2008)